SHAREHOLDER ALERT: The M&A Class Action Launches Investigation of the Merger - AVRO, CALB, MGRC, VINE
SHAREHOLDER ALERT: The M&A Class Action Launches Investigation of the Merger - AVRO, CALB, MGRC, VINE
PR Newswire
NEW YORK, Feb. 5, 2024
NEW YORK, Feb. 5, 2024 /PRNewswire/ -- Juan Monteverde, founder and managing partner of Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating:
- AVROBIO, Inc. (Nasdaq: AVRO), relating to its proposed merger with Tectonic Therapeutic, Inc. Under the terms of the agreement, AVRO shareholders are expected to own approximately 22.3% of the combined company. Click here for more information: https://www.monteverdelaw.com/case/avrobio-inc. It is free and there is no cost or obligation to you.
- California BanCorp (Nasdaq: CALB), relating to its proposed sale to Southern California Bancorp. Under the terms of the agreement, CALB shareholders are expected to receive 1.590 shares of Southern California common stock per share they own. Click here for more information: https://www.monteverdelaw.com/case/california-bancorp. It is free and there is no cost or obligation to you.
- McGrath RentCorp (Nasdaq: MGRC), relating to its proposed sale to WillScot Mobile Mini Holdings Corp. Under the terms of the agreement, MGRC shareholders will receive either $123.00 in cash or 2.8211 shares of WillScot per share they own. Click here for more information: https://www.monteverdelaw.com/case/mcgrath-rentcorp. It is free and there is no cost or obligation to you.
- Fresh Vine Wine Inc. (NYSE: VINE), relating to its proposed sale to Notes Live, Inc. Click here for more information: https://www.monteverdelaw.com/case/fresh-vine-wine-inc. It is free and there is no cost or obligation to you.
Before you hire a law firm, you should talk to a lawyer and ask:
- Do you recover money for shareholders?
- Do you litigate and go to Court?
- Do you even go to the office and wear a suit?
About Monteverde & Associates PC
Juan Monteverde is a Spaniard and a born fighter. Our firm litigates and has recovered money for shareholders… and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No company, director or officer is above the law. If you own common stock in any of the above listed companies and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341
Attorney Advertising. (C) 2024 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-launches-investigation-of-the-merger--avro-calb-mgrc-vine-302053919.html
SOURCE Monteverde & Associates PC
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise